Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jan 20, 2015
SAN DIEGO, Jan. 20, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares are being offered by Arena. Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.  ...
Jan 12, 2015
SAN DIEGO, Jan. 12, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient dosing in a Phase 2 clinical trial of ralinepag, an oral, non-prostanoid prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). "An intriguing component of this compoun...
Jan 9, 2015
SAN DIEGO, Jan. 9, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported on Eisai Inc.'s updated BELVIQ® marketing program with targeted new initiatives to address payers, patients and physicians. Encouraged by the increasing number of payers who have made the decision to provide formulary coverage for BELVIQ, E...
Jan 7, 2015
SAN DIEGO, Jan. 7, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from a Phase 1b multiple ascending dose clinical trial for APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. In the Phase 1b cl...
Jan 6, 2015
SAN DIEGO, Jan. 6, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time), at The Westin St. Francis Hotel in San Fr...
Nov 25, 2014
SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the US Patent and Trademark Office granted Arena U.S. Patent No. 8,895,776, entitled "Modulators of the Prostacyclin (PGI2) Receptor Useful for the Treatment of Disorders Related Thereto," covering ralinepag (formerly APD811), an orally availabl...
Nov 24, 2014
SAN DIEGO, Nov. 24, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), at The New York Palace Hotel in New York...
Nov 13, 2014
SAN DIEGO, Nov. 13, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), at The New York Palace Hotel in New York. A li...
Nov 6, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 6, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, ta...
Nov 5, 2014
SAN DIEGO, Nov. 5, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time), at The Arizona Biltmore in Phoenix, Arizona....
Nov 3, 2014
SAN DIEGO, Nov. 3, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2014. "The third quarter saw continued growth for BELVIQ® with prescriptions increasing by approximately 30% over the previous quarter," said Jack L...
Nov 3, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 3, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking cessation. The trial demonstrated statistically significant improvement over placebo in reducing...
Oct 31, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 31, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ® (lorcaserin HCl) CIV will be presented during ObesityWeekSM hosted by The Obesity Society and the American Society for Metabolic and Bariatric Surgery. The meeting is taking place Nov...
Oct 28, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 28, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of lorcaserin HCl, a serotonin 2C receptor agonist, when coadministered with phentermine HCl. The results of the investigational study demonstrate that the...
Oct 27, 2014
SAN DIEGO, Oct. 27, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Monday, November 3, 2014, to provide a corporate update and discuss third quarter 2014 financial results. Arena will release its financial results b...
Page: First Previous
...
...
Next Last
 
= add release to Briefcase